Poster 5033: Recapitulating the TME in Ex Vivo 3D Tumor Growth Assay

Patient-Derived Xenograft Screening in a Three-Dimensional Tumor Growth Assay incorporating Stromal Elements to Recapitulate the Human Tumor Microenvironment

Diandong (Simon) Jiang, Jane Wrigley, Sumanjeet Malhi, Jamie Wood, Stephanie Morton, Louise Wainwright, Lucy Harris, Jason King, Yinfei Yin, and Rajendra Kumari

The assessment of novel tumor microenvironment (TME) targeting therapies is currently hindered by a lack of preclinical in vitro and in vivo models which contain or incorporate human stromal cells.

To overcome this unmet preclinical need, CrownBio has developed a 3D-tumor growth assay (3D-TGA) in which patient-derived tumor cells are admixed with a basement membrane extract and human bone marrow-derived mesenchymal stem cells for novel agent screening.

This poster compares 3D-TGA activity results with in vivo subcutaneous response for the paired patient-derived xenograft models for a range of NSCLC standard of care (e.g. paclitaxel) and targeted (e.g. erlotinib) agents.

Read this Poster to Discover:

• That comparable sensitivities to test agents (e.g. paclitaxel, mTOR inhibitors, erlotinib, and carboplatin) are observed between the 3D-TGA and in vivo NSCLC xenograft studies
• That the relative potency between standard of care agents in the 3D-TGA correlates with in vivo efficacy data e.g. relative higher potency in the 3D-TGA relates to greater tumor inhibitory effect in vivo
• That human bone marrow-derived mesenchymal stem cells are required within the 3D–TGA to show comparable response to in vivo studies

Download the Poster Now!